Elinzanetant is a neurokinin-1,3 receptor antagonist (NK1/NK3) under development for managing vasomotor symptoms (VMS) associated with menopause. By targeting central thermoregulatory pathways, Elinzanetant offers a non-hormonal, once-daily treatment option for hot flashes and night sweats. It represents a promising innovation in women’s health and menopause management.

Explore Royal Pharma as your potential partner for Elinzanetant API.